Genmab to showcase latest blood cancer treatment advancements at 2025 american society of hematology (ash) annual meeting

Copenhagen, denmark--(business wire)--genmab a/s (nasdaq: gmab) today announced that more than 20 abstracts evaluating epcoritamab-bysp, a t-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and b-cell non-hodgkin's lymphoma (nhl) subtypes, will be presented at the 67th annual meeting and exposition of the american society of hematology (ash), in orlando, florida, and online, december 6-9. data from the epcoritamab development program will showcase its expan.
ASH Ratings Summary
ASH Quant Ranking